Premium
P1‐144: HIGH CSF A‐SYNUCLEIN IS ASSOCIATED WITH CLINICAL PROGRESSION IN PD PATIENTS
Author(s) -
Lindqvist Daniel,
Hall Sara,
Surova Yulia,
Öhrfelt Annika,
Hansson Oskar
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.381
Subject(s) - medicine , prospective cohort study , cerebrospinal fluid , cohort , parkinson's disease , cognitive decline , longitudinal study , disease , rating scale , cognition , population , psychology , pathology , psychiatry , dementia , developmental psychology , environmental health
p1⁄40.0010). Longitudinal analyses, using general linear mixed models with random intercepts/slopes, revealed Ab1-42 decreases in early/mid/late middle-age (p<0.01) in the FH+ group, and tau increases in mid/late middle-age (p<0.0001). The same patterns were observed in the FHgroup, albeit later (Ab1-42 in mid/late middle-age [p<0.01], tau in late middle-age [p<0.0001]). Overall, higher baseline values of bothAb1-42 and tauwere associated with faster rates of absolute change (p<0.001), with effects enhanced in APOE4 carriers.Conclusions:CSFbiomarker evidence ofADpathologies can be detected in cognitively normal middle-aged, individuals. Amyloid-related measures appear to change first, followed bymeasures of tangles and/or neurodegeneration, although within-subject analyses are needed to test this hypothesis. Characterizing the relationships among these changes and those of novel markers of neurodegeneration (VILIP-1), neuroinflammation (YKL-40), and amyloid imaging is in progress.